Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Harbour BioMed Joins $165M Cross Financing Round for Windward Bio to Advance Ultra-Long-Acting TSLP Immunotherapies

Fineline Cube May 8, 2026
Company Deals

Roche Acquires PathAI for $750M to Accelerate Digital Pathology and AI-Driven Diagnostic Transformation

Fineline Cube May 8, 2026
Company Deals

Bayer to Acquire Perfuse Therapeutics for Up to $2.45 Billion – Expands Ophthalmology Portfolio with Phase 2 Endothelin Receptor Antagonist

Fineline Cube May 7, 2026
Company Deals

Amoytop Biotech Launches RMB 1.53 Billion Convertible Bond Offering to Fuel R&D and Manufacturing Expansion

Fineline Cube May 7, 2026
Company Deals

Alebund Pharmaceuticals Files for Hong Kong IPO, Leveraging CKD-Focused Portfolio with Commercialized Mircera and Late-Stage Hyperphosphatemia Candidates

Fineline Cube May 6, 2026
Policy / Regulatory

China’s National Drug Alliance Procurement Office Suspends Harbin Liqiang’s Loxoprofen Gel Patch Production and Imposes 18-Month VBP Ban

Fineline Cube May 8, 2026
Company Drug

Huadong Medicine’s Asthma Drug CXG87 Receives NMPA Filing Acceptance Following Successful Phase III Trial Against Symbicort

Fineline Cube May 8, 2026
Company Drug

Wuhan YZY Biopharma’s Bispecific Antibody M701 Receives NMPA Acceptance for Review in Malignant Ascites Treatment

Fineline Cube May 8, 2026
Company Drug

SciClone’s Vibativ Approved by NMPA for HABP/VABP Treatment

Fineline Cube Feb 14, 2025

China-based SciClone Pharmaceuticals Inc. announced that it has received market approval from the National Medical...

Company Deals

Trinomab’s Antitetanus mAb Injection TNM002 Approved by NMPA

Fineline Cube Feb 14, 2025

China-based Trinomab Biotech Co., Ltd has received market approval for its antitetanus toxin monoclonal antibody...

Policy / Regulatory

NMPA Releases 90th Batch of Reference Drugs for GQCE

Fineline Cube Feb 14, 2025

The National Medical Products Administration (NMPA) has released the 90th batch of reference drugs for...

Company Drug

Accropeutics Doses First Patient in AC-101 Phase Ib UC Study

Fineline Cube Feb 14, 2025

Accro Bioscience (Suzhou) limited, better known as Accropeutics, a clinical-stage biotech operating out of New...

Policy / Regulatory

China Launches Major Public Health Initiatives to Enhance Healthcare Accessibility

Fineline Cube Feb 14, 2025

In a bid to bolster public health infrastructure and improve healthcare services, China’s National Health...

Company Drug

Sanofi and J&J’s E. coli Vaccine Fails Phase III Study

Fineline Cube Feb 14, 2025

France-based Sanofi (NASDAQ: SNY) and US giant Johnson & Johnson’s (J&J, NYSE: JNJ) vaccine candidate...

Company Drug

Antengene’s Xpovio Included in Taiwan’s NHI Drug List for Myeloma Treatment

Fineline Cube Feb 14, 2025

China-based biopharma Antengene Corp., Ltd (HKG: 6996) announced that its Xpovio (selinexor), the world’s first...

Company Deals

Boehringer Ingelheim Partners with ExpressionEdits on Gene Therapy Tech

Fineline Cube Feb 14, 2025

German pharmaceutical giant Boehringer Ingelheim has entered into a collaboration and licensing agreement with UK-based...

Company Drug

Merck’s Zerbaxa Approved by China’s NMPA for Complex Infections

Fineline Cube Feb 14, 2025

US-based pharmaceutical giant Merck, Sharp & Dohme Inc. (MSD, NYSE: MRK) announced that it has...

Policy / Regulatory

Hainan Unveils Biomedical New Technology Policy to Boost Medical Innovation

Fineline Cube Feb 13, 2025

In-Depth Analysis and Orientation Guide for Hainan’s Biomedical New Technology PolicyThe Hainan Provincial Health Commission,...

Company Drug

Roche’s Evrysdi Tablet Approved by FDA for Spinal Muscular Atrophy

Fineline Cube Feb 13, 2025

Swiss giant Roche (SWX: ROG) has announced that it has received marketing approval from the...

Policy / Regulatory

Shanghai’s Ambitious Plan to Revolutionize Brain-Computer Interfaces

Fineline Cube Feb 13, 2025

In-Depth Analysis and Orientation Guide for Shanghai’s Brain-Computer Interface (BCI) PolicyShanghai has unveiled a groundbreaking...

Company Drug

Pfizer’s Adcetris Gets New FDA Approval for Lymphoma Treatment

Fineline Cube Feb 13, 2025

US giant Pfizer (NYSE: PFE) has announced that it has received another indication approval from...

Company Deals

StairMed Raises Record RMB350m for Implantable BCI Development

Fineline Cube Feb 13, 2025

Shanghai StairMed Technology Co., Ltd., a specialist in implantable brain-computer interface (BCI) technology, has reportedly...

Company Drug

Lundbeck’s Amlenetug Receives FDA Fast Track for Multiple System Atrophy

Fineline Cube Feb 13, 2025

Denmark-based pharma company Lundbeck A/S (VIE: LUNB) has announced that it has received Fast Track...

Company Drug

OnCusp Therapeutics’ CUSP06 Receives FDA Fast Track for Ovarian Cancer

Fineline Cube Feb 13, 2025

Sino-US company OnCusp Therapeutics Inc. has announced that it has received Fast Track Designation (FTD)...

Company Deals

J&J Considers Selling Stroke Care Business Cerenovus for USD1-1.5 Billion

Fineline Cube Feb 13, 2025

US giant Johnson & Johnson (J&J, NYSE: JNJ) is reportedly considering selling its stroke care...

Company Deals

Anhui Anke to Invest in Visen Pharma’s Hong Kong IPO as Cornerstone Investor

Fineline Cube Feb 13, 2025

China – based Anhui Anke Biotechnology (Group) Co., Ltd (SHE: 300009) has announced its plan...

Company Drug

Boao Airport Customs Releases First Batch of Modulen IBD for Crohn’s Disease Management

Fineline Cube Feb 13, 2025

The Boao Airport Customs under Haikou Customs has released the first batch of 96 pieces...

Company Deals

AbbVie Collaborates with Xilio Therapeutics on Tumor-Activated Immunotherapies

Fineline Cube Feb 13, 2025

US pharmaceutical giant AbbVie (NYSE: ABBV) has announced a collaboration and option-to-license agreement with fellow...

Posts pagination

1 … 209 210 211 … 662

Recent updates

  • China’s National Drug Alliance Procurement Office Suspends Harbin Liqiang’s Loxoprofen Gel Patch Production and Imposes 18-Month VBP Ban
  • Harbour BioMed Joins $165M Cross Financing Round for Windward Bio to Advance Ultra-Long-Acting TSLP Immunotherapies
  • Huadong Medicine’s Asthma Drug CXG87 Receives NMPA Filing Acceptance Following Successful Phase III Trial Against Symbicort
  • Eli Lilly Reports 56% Revenue Surge in Q1 2026 Driven by Mounjaro and Zepbound Dominance, Raises Full-Year Guidance
  • Zai Lab Reports Q1 2026 Revenue Decline Amid Zejula Impact from Centralized Procurement, Offset by Xacduro Growth
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Policy / Regulatory

China’s National Drug Alliance Procurement Office Suspends Harbin Liqiang’s Loxoprofen Gel Patch Production and Imposes 18-Month VBP Ban

Company Deals

Harbour BioMed Joins $165M Cross Financing Round for Windward Bio to Advance Ultra-Long-Acting TSLP Immunotherapies

Company Drug

Huadong Medicine’s Asthma Drug CXG87 Receives NMPA Filing Acceptance Following Successful Phase III Trial Against Symbicort

Company

Eli Lilly Reports 56% Revenue Surge in Q1 2026 Driven by Mounjaro and Zepbound Dominance, Raises Full-Year Guidance

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.